Domains featuring this topic
Explore the domains where this topic appears.
Postdoctoral Research Fellowships in Biology (PRFB)
NSF postdoctoral fellowships supporting early-career scientists who combine artificial intelligence with biological research and training to advance biotechnology innovation.
Harnessing AI/ML for intelligent decision making in cell and gene therapy manufacturing
Irene Rombel discusses how artificial intelligence and machine learning can address bottlenecks, quality issues, and production costs in cell, gene, and RNA therapy manufacturing. The seminar focuses on real-world process-development applications that improve reproducibility, speed, and cost effectiveness.
Pharmacological exploitation of neurotrophins and their receptors to develop novel therapeutic approaches against neurodegenerative diseases and brain trauma
Neurotrophins (NGF, BDNF, NT-3) are endogenous growth factors that exert neuroprotective effects by preventing neuronal death and promoting neurogenesis. They act by binding to their respective high-affinity, pro-survival receptors TrkA, TrkB or TrkC, as well as to p75NTR death receptor. While these molecules have been shown to significantly slow or prevent neurodegeneration, their reduced bioavailability and inability to penetrate the blood-brain-barrier limit their use as potential therapeutics. To bypass these limitations, our research team has developed and patented small-sized, lipophilic compounds which selectively resemble neurotrophins’ effects, presenting preferable pharmacological properties and promoting neuroprotection and repair against neurodegeneration. In addition, the combination of these molecules with 3D cultured human neuronal cells, and their targeted delivery in the brain ventricles through soft robotic systems, could offer novel therapeutic approaches against neurodegenerative diseases and brain trauma.
Why dendrites matter for biological and artificial circuits
Learning with dendrites in brains and machine
In vitro bioelectronic models of the gut-brain axis
The human gut microbiome has emerged as a key player in the bidirectional communication of the gut-brain axis, affecting various aspects of homeostasis and pathophysiology. Until recently, the majority of studies that seek to explore the mechanisms underlying the microbiome-gut-brain axis cross-talk relied almost exclusively on animal models, and particularly gnotobiotic mice. Despite the great progress made with these models, various limitations, including ethical considerations and interspecies differences that limit the translatability of data to human systems, pushed researchers to seek for alternatives. Over the past decades, the field of in vitro modelling of tissues has experienced tremendous growth, thanks to advances in 3D cell biology, materials, science and bioengineering, pushing further the borders of our ability to more faithfully emulate the in vivo situation. Organ-on-chip technology and bioengineered tissues have emerged as highly promising alternatives to animal models for a wide range of applications. In this talk I’ll discuss our progress towards generating a complete platform of the human microbiota-gut-brain axis with integrated monitoring and sensing capabilities. Bringing together principles of materials science, tissue engineering, 3D cell biology and bioelectronics, we are building advanced models of the GI and the BBB /NVU, with real-time and label-free monitoring units adapted in the model architecture, towards a robust and more physiologically relevant human in vitro model, aiming to i) elucidate the role of microbiota in the gut-brain axis communication, ii) to study how diet and impaired microbiota profiles affect various (patho-)physiologies, and iii) to test personalised medicine approaches for disease modelling and drug testing.
Virtual launch and webinar: Magnetic Particle Imaging at Monash University
Magnetic Particle Imaging (MPI) is a new non-invasive imaging technique with significantly increased sensitivity over MRI and faster acquisition times than PET and MRI. The MPI capability at the Alfred Research Alliance - Monash Biomedical Imaging site in Melbourne, Australia, is the world’s first MPI system with Computed Tomography (CT) and Hyperthermia capabilities. It provides unique capabilities that open the door to cutting-edge opportunities for interdisciplinary projects in medical research, chemistry and biotechnology. The webinar will involve: * official launch of Magnetic Particle Imaging at Monash University * the MPI system supplier, Magnetic Insight, discussing the world first technology and its potential * presentations from key researchers outlining MPI applications and the benefits of utilising the technology.